SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
4th Jun 20148:32 amRNSNotice of AGM
7th May 20145:05 pmRNSHolding(s) in Company
7th May 201412:03 pmRNSHolding(s) in Company
29th Apr 20144:30 pmRNSResult of Placing
28th Apr 20145:21 pmRNSProposed Placing to raise a minimum of £10 million
28th Apr 20147:00 amRNSGene knockdown in non-human primates
19th Mar 20147:02 amRNSPotential Equity Fundraising
19th Mar 20147:00 amRNSPreliminary Results - Year Ended 31 December 2013
27th Feb 20147:00 amRNSYear end trading update
26th Feb 201412:09 pmRNSHolding(s) in Company
24th Feb 20143:41 pmRNSHolding(s) in Company
23rd Jan 201411:35 amRNSHolding(s) in Company
4th Dec 201311:39 amRNSHolding(s) in Company
22nd Nov 20134:00 pmRNSHolding(s) in Company
21st Nov 20136:25 pmRNSHolding(s) in Company
20th Nov 20135:00 pmRNSGrant of Options and Additional Listing
18th Nov 20137:02 amRNSInvestor Event and Appointment of NOMAD
18th Nov 20137:01 amRNSDirectorate and senior management changes
18th Nov 20137:00 amRNSNew Clinical Trial
8th Nov 20135:33 pmRNSHolding(s) in Company
5th Nov 20137:00 amRNSHolding(s) in Company
23rd Oct 20137:00 amRNSInvestor Day
17th Oct 20135:50 pmRNSHolding(s) in Company
17th Oct 20135:50 pmRNSHolding(s) in Company
17th Oct 20135:50 pmRNSHolding(s) in Company
23rd Sep 20138:33 amRNSHalf Yearly Report
19th Sep 20137:00 amRNSDate of Interim Announcement
30th Aug 20132:46 pmRNSHolding(s) in Company
21st Aug 20137:00 amRNSDirectorate Change
16th Aug 201312:29 pmRNSHolding(s) in Company
8th Aug 20137:00 amRNSAtu027 Phase I/II Update
12th Jul 20134:32 pmRNSHolding(s) in Company
3rd Jul 20137:00 amRNSCancellation of warrants
26th Jun 20132:47 pmRNSResult of AGM
26th Jun 20139:00 amRNSIssue of Options
26th Jun 20137:00 amRNSDirectorate Change
18th Jun 20137:00 amRNSAtu027 update: progression into Phase IIa
7th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 201311:30 amRNSNotice of AGM
29th May 20137:01 amRNSFinal Results
29th May 20137:00 amRNSDirectorate Change
2nd May 20134:52 pmRNSHolding(s) in Company
2nd May 20133:55 pmRNSHolding(s) in Company
2nd May 20133:52 pmRNSHolding(s) in Company
2nd May 20133:26 pmRNSHolding(s) in Company
29th Apr 201312:15 pmRNSResult of EGM
10th Apr 20137:00 amRNSPlacing and Share Consolidation
8th Mar 20137:00 amRNSExercise of warrants
5th Mar 20139:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.